BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 32284990)

  • 1. Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acid-induced differentiation.
    Ravasio R; Ceccacci E; Nicosia L; Hosseini A; Rossi PL; Barozzi I; Fornasari L; Zuffo RD; Valente S; Fioravanti R; Mercurio C; Varasi M; Mattevi A; Mai A; Pavesi G; Bonaldi T; Minucci S
    Sci Adv; 2020 Apr; 6(15):eaax2746. PubMed ID: 32284990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low HOX gene expression in PML-RARα-positive leukemia results from suppressed histone demethylation.
    Rejlova K; Musilova A; Kramarzova KS; Zaliova M; Fiser K; Alberich-Jorda M; Trka J; Starkova J
    Epigenetics; 2018; 13(1):73-84. PubMed ID: 29224413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia.
    Schenk T; Chen WC; Göllner S; Howell L; Jin L; Hebestreit K; Klein HU; Popescu AC; Burnett A; Mills K; Casero RA; Marton L; Woster P; Minden MD; Dugas M; Wang JC; Dick JE; Müller-Tidow C; Petrie K; Zelent A
    Nat Med; 2012 Mar; 18(4):605-11. PubMed ID: 22406747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-
    Smitheman KN; Severson TM; Rajapurkar SR; McCabe MT; Karpinich N; Foley J; Pappalardi MB; Hughes A; Halsey W; Thomas E; Traini C; Federowicz KE; Laraio J; Mobegi F; Ferron-Brady G; Prinjha RK; Carpenter CL; Kruger RG; Wessels L; Mohammad HP
    Haematologica; 2019 Jun; 104(6):1156-1167. PubMed ID: 30514804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knockdown of SALL4 Protein Enhances All-trans Retinoic Acid-induced Cellular Differentiation in Acute Myeloid Leukemia Cells.
    Liu L; Liu L; Leung LH; Cooney AJ; Chen C; Rosengart TK; Ma Y; Yang J
    J Biol Chem; 2015 Apr; 290(17):10599-609. PubMed ID: 25737450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia.
    Przespolewski A; Wang ES
    Expert Opin Investig Drugs; 2016 Jul; 25(7):771-80. PubMed ID: 27077938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML.
    Barth J; Abou-El-Ardat K; Dalic D; Kurrle N; Maier AM; Mohr S; Schütte J; Vassen L; Greve G; Schulz-Fincke J; Schmitt M; Tosic M; Metzger E; Bug G; Khandanpour C; Wagner SA; Lübbert M; Jung M; Serve H; Schüle R; Berg T
    Leukemia; 2019 Jun; 33(6):1411-1426. PubMed ID: 30679800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia.
    Maiques-Diaz A; Spencer GJ; Lynch JT; Ciceri F; Williams EL; Amaral FMR; Wiseman DH; Harris WJ; Li Y; Sahoo S; Hitchin JR; Mould DP; Fairweather EE; Waszkowycz B; Jordan AM; Smith DL; Somervaille TCP
    Cell Rep; 2018 Mar; 22(13):3641-3659. PubMed ID: 29590629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth suppression of acute promyelocytic leukemia cells having increased expression of the non-rearranged alleles: RAR alpha or PML.
    Ahn MJ; Nason-Burchenal K; Moasser MM; Dmitrovsky E
    Oncogene; 1995 Jun; 10(12):2307-14. PubMed ID: 7784078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel LSD1 Inhibitor T-3775440 Disrupts GFI1B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML Cells.
    Ishikawa Y; Gamo K; Yabuki M; Takagi S; Toyoshima K; Nakayama K; Nakayama A; Morimoto M; Miyashita H; Dairiki R; Hikichi Y; Tomita N; Tomita D; Imamura S; Iwatani M; Kamada Y; Matsumoto S; Hara R; Nomura T; Tsuchida K; Nakamura K
    Mol Cancer Ther; 2017 Feb; 16(2):273-284. PubMed ID: 27903753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RARα2 and PML-RAR similarities in the control of basal and retinoic acid induced myeloid maturation of acute myeloid leukemia cells.
    Gianni M; Fratelli M; Bolis M; Kurosaki M; Zanetti A; Paroni G; Rambaldi A; Borleri G; Rochette-Egly C; Terao M; Garattini E
    Oncotarget; 2017 Jun; 8(23):37041-37060. PubMed ID: 27419624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML.
    Kahl M; Brioli A; Bens M; Perner F; Kresinsky A; Schnetzke U; Hinze A; Sbirkov Y; Stengel S; Simonetti G; Martinelli G; Petrie K; Zelent A; Böhmer FD; Groth M; Ernst T; Heidel FH; Scholl S; Hochhaus A; Schenk T
    Leukemia; 2019 Nov; 33(11):2628-2639. PubMed ID: 31576004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Granulocytic differentiation of human NB4 promyelocytic leukemia cells induced by all-trans retinoic acid metabolites.
    Idres N; Benoît G; Flexor MA; Lanotte M; Chabot GG
    Cancer Res; 2001 Jan; 61(2):700-5. PubMed ID: 11212271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nascent transcript and single-cell RNA-seq analysis defines the mechanism of action of the LSD1 inhibitor INCB059872 in myeloid leukemia.
    Johnston G; Ramsey HE; Liu Q; Wang J; Stengel KR; Sampathi S; Acharya P; Arrate M; Stubbs MC; Burn T; Savona MR; Hiebert SW
    Gene; 2020 Aug; 752():144758. PubMed ID: 32422235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selenite promotes all-trans retinoic acid-induced maturation of acute promyelocytic leukemia cells.
    Misra S; Selvam AK; Wallenberg M; Ambati A; Matolcsy A; Magalhaes I; Lauter G; Björnstedt M
    Oncotarget; 2016 Nov; 7(46):74686-74700. PubMed ID: 27732960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines.
    Murray-Stewart T; Woster PM; Casero RA
    Amino Acids; 2014 Mar; 46(3):585-94. PubMed ID: 23508577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells.
    Fiskus W; Sharma S; Shah B; Portier BP; Devaraj SG; Liu K; Iyer SP; Bearss D; Bhalla KN
    Leukemia; 2014 Nov; 28(11):2155-64. PubMed ID: 24699304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Common defects of different retinoic acid resistant promyelocytic leukemia cells are persistent telomerase activity and nuclear body disorganization.
    Nason-Burchenal K; Maerz W; Albanell J; Allopenna J; Martin P; Moore MA; Dmitrovsky E
    Differentiation; 1997 Aug; 61(5):321-31. PubMed ID: 9342843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia.
    Ferrara FF; Fazi F; Bianchini A; Padula F; Gelmetti V; Minucci S; Mancini M; Pelicci PG; Lo Coco F; Nervi C
    Cancer Res; 2001 Jan; 61(1):2-7. PubMed ID: 11196162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Basic and clinical studies of the gene product-targeting therapy based on leukemogenesis--editorial].
    Chen SJ; Chen LJ; Zhou GB
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb; 13(1):1-8. PubMed ID: 15748426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.